AU2012301769B2 - FGF21 for use in treating type 1 diabetes - Google Patents

FGF21 for use in treating type 1 diabetes Download PDF

Info

Publication number
AU2012301769B2
AU2012301769B2 AU2012301769A AU2012301769A AU2012301769B2 AU 2012301769 B2 AU2012301769 B2 AU 2012301769B2 AU 2012301769 A AU2012301769 A AU 2012301769A AU 2012301769 A AU2012301769 A AU 2012301769A AU 2012301769 B2 AU2012301769 B2 AU 2012301769B2
Authority
AU
Australia
Prior art keywords
fgf21
polypeptide
variant
human
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012301769A
Other languages
English (en)
Other versions
AU2012301769A1 (en
Inventor
Murielle Marie Ellison
Shanaka STANISLAUS
Jing Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2012301769A1 publication Critical patent/AU2012301769A1/en
Application granted granted Critical
Publication of AU2012301769B2 publication Critical patent/AU2012301769B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2012301769A 2011-08-31 2012-08-30 FGF21 for use in treating type 1 diabetes Active AU2012301769B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161529641P 2011-08-31 2011-08-31
US61/529,641 2011-08-31
PCT/US2012/053216 WO2013033452A2 (en) 2011-08-31 2012-08-30 Method of treating or ameliorating type 1 diabetes using fgf21

Publications (2)

Publication Number Publication Date
AU2012301769A1 AU2012301769A1 (en) 2014-02-27
AU2012301769B2 true AU2012301769B2 (en) 2016-05-19

Family

ID=46964016

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012301769A Active AU2012301769B2 (en) 2011-08-31 2012-08-30 FGF21 for use in treating type 1 diabetes

Country Status (7)

Country Link
US (2) US20140213512A1 (enExample)
EP (1) EP2750695A2 (enExample)
JP (2) JP2014526441A (enExample)
AU (1) AU2012301769B2 (enExample)
CA (1) CA2845357A1 (enExample)
MX (1) MX2014002260A (enExample)
WO (1) WO2013033452A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
JP5767314B2 (ja) 2010-04-16 2015-08-19 ソーク インスティチュート フォー バイオロジカル スタディーズ Ｆｇｆを用いて代謝障害を処置するための方法
HUE045629T2 (hu) 2011-07-01 2020-01-28 Ngm Biopharmaceuticals Inc Készítmények, alkalmazások és eljárások anyagcsere rendellenességek és betegségek kezelésére
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
CA2892152A1 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
CA2928135A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
RU2707531C2 (ru) 2013-10-28 2019-11-27 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Модели рака и соответствующие способы
KR102489475B1 (ko) 2014-01-24 2023-01-20 엔지엠 바이오파마슈티컬스, 아이엔씨. 결합 단백질 및 그의 사용 방법
JP6712230B2 (ja) * 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
US10519240B2 (en) 2014-03-25 2019-12-31 Regeneron Pharmaceuticals, Inc. Anti-FGFR1c antibody-FGF21 fusion proteins
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016039339A1 (ja) * 2014-09-08 2016-03-17 国立大学法人大阪大学 脱髄疾患の予防又は治療剤
US10973931B2 (en) 2014-09-16 2021-04-13 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
WO2016048999A2 (en) * 2014-09-23 2016-03-31 Salk Institute For Biological Studies Fgf21 truncations and mutants and uses thereof
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
RU2729161C2 (ru) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
CA2972128A1 (en) * 2014-12-23 2016-06-30 Novo Nordisk A/S Fgf21 derivatives and uses thereof
EP3978614A3 (en) 2015-01-07 2022-07-27 Universitat Autònoma de Barcelona Single-vector gene construct comprising insulin and glucokinase genes
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP2018529729A (ja) * 2015-10-01 2018-10-11 アムジエン・インコーポレーテツド 胆汁酸障害の処置
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
EP3368059A4 (en) 2015-10-30 2019-03-27 Salk Institute for Biological Studies TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) -1 ANALOGUE
ES2871036T3 (es) * 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Método para el tratamiento de trastornos relacionados con ácidos biliares
WO2017180988A2 (en) * 2016-04-15 2017-10-19 Indiana University Research And Technology Corporation Fgf21 c-terminal peptide optimization
CN117535350A (zh) * 2016-05-20 2024-02-09 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
EP3568149B1 (en) 2016-11-10 2025-03-12 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
WO2018166461A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
KR102664780B1 (ko) 2017-04-21 2024-05-13 주식회사유한양행 이중 작용 단백질 및 그의 유도체의 제조방법
CN107056925B (zh) * 2017-04-28 2022-01-14 中国科学院合肥物质科学研究院 人fgf21突变体、其制备方法及用途
WO2018215613A1 (en) * 2017-05-24 2018-11-29 Universitat Autonoma De Barcelona Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence
KR102765034B1 (ko) * 2017-05-24 2025-02-11 유니버시타트 아우토노마 데 바르셀로나 섬유아세포 성장 인자 21 (ｆｇｆ21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트
CN116098989A (zh) 2018-02-08 2023-05-12 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
CN114853908B (zh) 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
WO2021139763A1 (zh) * 2020-01-08 2021-07-15 上海翰森生物医药科技有限公司 Fgf21突变体蛋白及其融合蛋白
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN117586423A (zh) 2021-07-14 2024-02-23 北京质肽生物医药科技有限公司 用于代谢病症的融合多肽
CN113980147B (zh) * 2021-11-26 2023-07-28 中国药科大学 一种聚多肽与fgf21融合蛋白突变体及其应用
WO2024059507A1 (en) * 2022-09-12 2024-03-21 Akero Therapeutics, Inc. Fgf21 mutant polypeptides
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259780A1 (en) * 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
WO2008121563A2 (en) * 2007-03-30 2008-10-09 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
WO2010042747A2 (en) * 2008-10-10 2010-04-15 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129503A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
CN101072577B (zh) 2004-10-07 2013-12-18 加利福尼亚大学董事会 ShK毒素类似物及其在选择性抑制Kv1.3钾通道中的应用
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
JP2012525847A (ja) * 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
US8324160B2 (en) 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
JP2013512672A (ja) 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
MX2012011986A (es) 2010-04-15 2013-03-05 Amgen Inc RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259780A1 (en) * 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
WO2008121563A2 (en) * 2007-03-30 2008-10-09 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
WO2010042747A2 (en) * 2008-10-10 2010-04-15 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129503A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XU, J. et al., 2009, Am J Physiol Endocrinol Metab 297: E1105-E1114, doi:10.1152/ ajpendo.00348.2009. *

Also Published As

Publication number Publication date
EP2750695A2 (en) 2014-07-09
WO2013033452A2 (en) 2013-03-07
US20180000898A1 (en) 2018-01-04
MX2014002260A (es) 2014-08-18
CA2845357A1 (en) 2013-03-07
AU2012301769A1 (en) 2014-02-27
WO2013033452A3 (en) 2013-04-25
JP2017226665A (ja) 2017-12-28
US20140213512A1 (en) 2014-07-31
JP2014526441A (ja) 2014-10-06

Similar Documents

Publication Publication Date Title
AU2012301769B2 (en) FGF21 for use in treating type 1 diabetes
US20200325200A1 (en) Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP2621515B1 (en) A chimeric seal-human leptin polypeptide with increased solubility
JP2002531089A (ja) 赤血球産生性化合物
US9474792B2 (en) Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
AU2020281098A1 (en) Methods and compositions for treatment of cartilage damage and arthritis
DK2618830T3 (en) Formulations to a kvæggranulocytkolonistimulerende factor and variants thereof
HK1188711B (en) A chimeric seal-human leptin polypeptide with increased solubility
HK1188711A (en) A chimeric seal-human leptin polypeptide with increased solubility

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)